NovusPharma’s Pixantrone Regimen produces high response rates in relapsed aggressive lymphoma Sofinnova

The News

NovusPharma’s Pixantrone Regimen produces high response rates in relapsed aggressive lymphoma

07/07/2003

Visit website www.novuspharma.com Download file 121_fichier_attache.pdf

2003

25/02/2003
ESMERTEC acquires Insignia JVM business assets and becomes master distributor of Insignia’s Java Virtual Machine solution e
20/03/2003
Sofinnova Partners and Sofinnova Ventures Host Inaugural CEO Day Conference
17/04/2003
Diatos expands its management team
28/04/2003
Jean-Bernard Schmidt says Europe's post-bubble VCs now have the right focus: "Technology and funding seed startups" : interview for BusinessWeek
02/05/2003
Ingenium publishes in Science groundbreaking results about the pathogenetic cause for motor neuron disease
14/05/2003
Novuspharma SpA Announces Financial Results for the Three Months Ended 31 March 2003
05/06/2003
Jean-Bernard Schmidt elected as Association Chairman in 20th year of EVCA
05/06/2003
FT.com : "Challenge for Schmidt in private equity"
05/06/2003
l'Agefi : Jean-Bernard Schmidt, un "venture capitalist" viscéral à la tête de l'association européenne du capital investissement
17/06/2003
Cell Therapeutics, Inc. (CTI) Adds Pixantrone to its Oncology Drug Pipeline and Extends Global Cancer Business through Merger with Novuspharma S.p.a.
07/07/2003
NovusPharma’s Pixantrone Regimen produces high response rates in relapsed aggressive lymphoma
28/07/2003
Servista enables Lloyds TSB to launch home energy and telephone services
07/08/2003
Novuspharma SpA Announces Financial Results for the Six Months Ended 30 June 2003
30/06/2003
Q2 Another Record for AtomZ
02/09/2003
Ingenium Appoints Dr. Klaus Dembowsky to Vice President Drug Discovery
10/09/2003
Neuro3d raises M€ 10 from Existing Shareholders
30/09/2003
Novuspharma Press Release: Financial Results for the nine months ended 30 September 2003
23/10/2003
Cell Therapeutics, Inc. and Novuspharma S.p.A Announce Shareholder Approval of Merger
28/10/2003
Cellzome Announces Research Collaboration with Johnson & Johnson R&D
13/11/2003
Esmertec Nets €23m in Over-Subscribed Funding Round
25/11/2003
IDM obtient un deuxième brevet au Japon
14/11/2003
Innate Pharma and Novo Nordisk A/S sign licensing deal which opensnew avenue in cancer immunotherapy
19/11/2003
Allergan et Exonhit initient leur premier criblage à haut flux sur une cible identifiée conjointement
19/11/2003
Allergan and Exonhit designate target for high throughput screening
02/12/2003
The pharmaceutical company Biolipox strengthens Board of Directors with a well known industrialist
10/12/2003
Addex Pharmaceuticals SA Signs Three year Clinical Development Partnership with Fulcrum Pharma
12/12/2003
Pixantrone Induces Impressive 77% Major Tumor Response Rate in Patients with Relapsed Aggressive Lymphoma when Substituted for Doxorubicin in CHOP Regimen
29/12/2003
Happy New Year 2004 !
19/12/2003
France Biotech Applauds the French Parliament’ Vote on the Status of the Young Innovative Company (YIC) in the 2004 Budget Bill
19/12/2003
France Biotech se réjouit de l'adoption du statut de la jeune entreprise innovante dans la loi de finance 2004

Click here for the site of Sofinnova Ventures, our sister firm in San Francisco http://www.sofinnova.com